-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

The growth rate of petrol consumption is set to fall below 5% in the current fiscal, the first time in five years. Meanwhile, the consumption of diesel continues to grow at 7%, adding to the losses of the oil marketing companies on account of subsidies. In India, diesel is subsidized while petrol is not, and the price difference has led to more buyers opting for vehicles driven by the cheaper fuel. According...

Bowing to the clamour for scrutiny of the accounts of private power distribution companies operating in the city, the Delhi government has finally approved their audit by the Comptroller and Auditor General (CAG). According to a cabinet note, the government sanctioned an audit of the three discoms — BSES Yamuna and Rajdhani, and NDPL — “since inception.” The decision to get a CAG audit carried out was disclosed during a hearing in...

-The Economic Times   The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say.  On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...